PGNY Key Statistics, Chart & Performance
The current stock price of PGNY is 26.37 USD. In the past month the price increased by 41.39%. In the past year, price increased by 69.36%.
PGNY Latest News, Press Relases and Analysis
PGNY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| UNH | UNITEDHEALTH GROUP INC | 15.7 | 298.72B | ||
| ELV | ELEVANCE HEALTH INC | 11.03 | 75.17B | ||
| HUM | HUMANA INC | 12.98 | 29.56B | ||
| CNC | CENTENE CORP | 9.74 | 19.34B | ||
| HQY | HEALTHEQUITY INC | 29.88 | 9.06B | ||
| MOH | MOLINA HEALTHCARE INC | 8.04 | 7.62B | ||
| ALHC | ALIGNMENT HEALTHCARE INC | N/A | 3.84B | ||
| CLOV | CLOVER HEALTH INVESTMENTS CO | N/A | 1.29B |
Related stock screener links
About PGNY
Company Profile
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 675 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Company Info
PROGYNY INC
1359 Broadway
New York City NEW YORK 10018 US
CEO: David Schlanger
Employees: 678
Phone: 12128883124
PROGYNY INC / PGNY FAQ
What does PGNY do?
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 675 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
What is the current price of PGNY stock?
The current stock price of PGNY is 26.37 USD. The price decreased by -1.24% in the last trading session.
Does PROGYNY INC pay dividends?
PGNY does not pay a dividend.
What is the ChartMill rating of PROGYNY INC stock?
PGNY has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How many employees does PROGYNY INC have?
PROGYNY INC (PGNY) currently has 678 employees.
What is the market capitalization of PGNY stock?
PROGYNY INC (PGNY) has a market capitalization of 2.27B USD. This makes PGNY a Mid Cap stock.
PGNY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PGNY. When comparing the yearly performance of all stocks, PGNY is one of the better performing stocks in the market, outperforming 91.57% of all stocks.
PGNY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PGNY. PGNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
PGNY Financial Highlights
Over the last trailing twelve months PGNY reported a non-GAAP Earnings per Share(EPS) of 0.63. The EPS increased by 8.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.46% | ||
| ROA | 7.11% | ||
| ROE | 10.1% | ||
| Debt/Equity | 0 |
PGNY Forecast & Estimates
16 analysts have analysed PGNY and the average price target is 29.35 USD. This implies a price increase of 11.31% is expected in the next year compared to the current price of 26.37.
For the next year, analysts expect an EPS growth of 10.72% and a revenue growth 9.74% for PGNY